Lyra Therapeutics, Inc. (LYRA) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
LYRA Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 9, 2026, Lyra Therapeutics, Inc. (LYRA) trades at a price-to-earnings ratio of -0.3x, with a stock price of $0.44 and trailing twelve-month earnings per share of $-18.64.
Compared to the Healthcare sector median P/E of 21.9x, LYRA trades at a 101% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, LYRA trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our LYRA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
LYRA P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $74M | 12.0Lowest | - | +103% | |
| $275B | 15.3 | 0.72Best | +8% | |
| $283B | 28.0 | 1.28 | +191%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
See LYRA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LYRA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LYRA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLYRA — Frequently Asked Questions
Quick answers to the most common questions about buying LYRA stock.
Is LYRA stock overvalued or undervalued?
LYRA current P/E: -0.3x. 5-year average P/E: N/A. Percentile: N/A.
How does LYRA's valuation compare to peers?
Lyra Therapeutics, Inc. P/E of -0.3x compares to sector median of 21.9x. The discount suggests lower growth expectations or higher risk.
What is LYRA's PEG ratio?
LYRA PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.